MX2009012420A - Reovirus mutantes y metodos para elaboracion y uso. - Google Patents

Reovirus mutantes y metodos para elaboracion y uso.

Info

Publication number
MX2009012420A
MX2009012420A MX2009012420A MX2009012420A MX2009012420A MX 2009012420 A MX2009012420 A MX 2009012420A MX 2009012420 A MX2009012420 A MX 2009012420A MX 2009012420 A MX2009012420 A MX 2009012420A MX 2009012420 A MX2009012420 A MX 2009012420A
Authority
MX
Mexico
Prior art keywords
methods
mutant reovirus
mutant
making
isvp
Prior art date
Application number
MX2009012420A
Other languages
English (en)
Spanish (es)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of MX2009012420A publication Critical patent/MX2009012420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009012420A 2007-05-21 2008-05-21 Reovirus mutantes y metodos para elaboracion y uso. MX2009012420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93925507P 2007-05-21 2007-05-21
PCT/CA2008/000964 WO2008141448A1 (en) 2007-05-21 2008-05-21 Mutant reoviruses and methods of making and using

Publications (1)

Publication Number Publication Date
MX2009012420A true MX2009012420A (es) 2009-12-09

Family

ID=40031362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012420A MX2009012420A (es) 2007-05-21 2008-05-21 Reovirus mutantes y metodos para elaboracion y uso.

Country Status (14)

Country Link
US (1) US20080292594A1 (enExample)
EP (1) EP2150613B1 (enExample)
JP (1) JP2010527593A (enExample)
CN (2) CN104195115A (enExample)
AR (1) AR066649A1 (enExample)
AU (1) AU2008253505B2 (enExample)
CA (1) CA2680661C (enExample)
DK (1) DK2150613T3 (enExample)
ES (1) ES2611455T3 (enExample)
IL (1) IL200690A (enExample)
MX (1) MX2009012420A (enExample)
TW (1) TW200909581A (enExample)
WO (1) WO2008141448A1 (enExample)
ZA (1) ZA200907017B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720624D0 (en) * 2007-10-20 2007-11-28 Academisch Ziekenhuis Leiden Viral Modification
JP2011500608A (ja) * 2007-10-22 2011-01-06 オンコリティクス バイオテク，インコーポレーテッド 増殖性障害の治療レジメン
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
CA2723587C (en) * 2008-05-27 2017-09-26 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
ES2630012T3 (es) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
EP3068411B1 (en) 2013-11-15 2020-03-18 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis
KR20210098202A (ko) * 2020-01-31 2021-08-10 바이로큐어 주식회사 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물
KR20220090467A (ko) * 2020-12-22 2022-06-29 바이로큐어 주식회사 신규한 변형 레오바이러스 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
DE69937999T2 (de) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
CA2428206C (en) * 2000-11-09 2005-09-27 Oncolytics Biotech Inc. Methods for the treatment of cellular proliferative disorders
JP4087712B2 (ja) * 2001-03-16 2008-05-21 オンコリティクス バイオテック， インコーポレイティッド 細胞培養物からウイルスを抽出する方法
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US10260049B2 (en) * 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus

Also Published As

Publication number Publication date
EP2150613B1 (en) 2016-10-19
US20080292594A1 (en) 2008-11-27
IL200690A0 (en) 2011-08-01
DK2150613T3 (en) 2017-01-30
CN104195115A (zh) 2014-12-10
HK1136006A1 (en) 2010-06-18
AU2008253505A1 (en) 2008-11-27
ZA200907017B (en) 2010-12-29
WO2008141448A1 (en) 2008-11-27
EP2150613A4 (en) 2011-01-19
TW200909581A (en) 2009-03-01
CA2680661C (en) 2018-05-29
CA2680661A1 (en) 2008-11-27
IL200690A (en) 2014-02-27
AR066649A1 (es) 2009-09-02
ES2611455T3 (es) 2017-05-09
EP2150613A1 (en) 2010-02-10
AU2008253505B2 (en) 2014-09-04
CN101679953A (zh) 2010-03-24
JP2010527593A (ja) 2010-08-19

Similar Documents

Publication Publication Date Title
MX2009012420A (es) Reovirus mutantes y metodos para elaboracion y uso.
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006576A (es) Composiciones y metodos para producir isopreno.
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2009009598A (es) Reovirus que tienen secuencias modificadas.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
IN2012DN00908A (enExample)
MX2010004374A (es) Armazones proteinicos.
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
MY147661A (en) Fused bicycloheterocycle substituted azabicyclic alkane derivatives
PL1836169T3 (pl) Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
MY161495A (en) Virus like particle compositions and methods of use
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
MX379863B (es) Composiciones y metodos relacionados con una toxina mutante de clostridium difficile
TN2011000655A1 (en) Mesenchymal stem cell differentiation
MX2010002028A (es) Metodos y composiciones para modular celulas t.
PL1877390T3 (pl) Związki benzizoksazolopiperazynowe i sposoby ich stosowania
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
PH12023500023A1 (en) Cdk2 degraders and uses thereof
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
IN2015MN00027A (enExample)

Legal Events

Date Code Title Description
FG Grant or registration